All Episodes
Melanoma Matters — 93 episodes
Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)
Ep 86: Teaser Tudriqev (RP1) FDA Approval
Ep 87: INTerpath-001 Press Release - August 2026
Ep 86: Tudriqev (RP1) FDA Approval
Ep 85: Surgical considerations for TIL
Ep 84: Merlin CP-GEP and Castle i31-SLNB tests
Ep 83: Guest Megan Othus and Time of Day Administration
Ep 82: Best of ASCO: 2026
Live from ASCO 2026: a preview
Ep 81: IGNYTE trial (RP1 + nivo)
Ep 80: 2025 Holiday Special
Ep 79: coBRIM, COMBI-d 5-year follow-up
Ep 78 TRAILER: MEK inhibitor trials
Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib)
Ep 77: Guest Merrick Ross
Ep 76: KEYNOTE 054 7-year follow-up
Ep 75: Immune-mediated Myocarditis
Ep 74: Best of ESMO 2025: Part 2 of 2
Ep 73: Best of ESMO 2025: Part 1 of 2
ESMO 2025 preview
Ep 72 TRAILER: Quiz show - new drug approvals in 2024
Ep 72: Quiz show - new drug approvals in 2024 (yes we're late...)
Ep 71: Women in Melanoma manuscript - now with a FACT CHECK!
Ep 70: Best of ASCO colon.... 2025 ;)
Ep 69: Guest Monty Pal
Ep 68: GDF-15 antibody GODFATHER trial
Ep 67: SITC white paper on ICI resistance
Ep 66: Ponsegromab for cancer cachexia
Ep 65: Opdivo Qvantig (subcutaneous formulation)
Ep 64: Guest Clare Turnbull Part 2
Ep 63: Guest Clare Turnbull Part 1
Ep 62: Post PD-1 studies
Ep 61: Guest Inge Marie Svane
Ep 60: Melanoma & Kidney Cancer w/ Mike Atkins
Ep 59: 2024 Reflections
Ep 58: Best of 2024: SMR
Ep 57: Best of 2024: ESMO
Ep 56: Best of 2024: ASCO
Ep 55: VIBE Intro - Give Us Your Feedback
Ep 54: All things MSLT with Mark Faries
Ep 53: Guest Toni Ribas
Ep 52: COLUMBUS 7-year follow-up
Ep 51: Exercise Oncology and TIL for CNS mets with Allison Betof Warner
Ep 50: ADAPT-IT Study
Ep 49: Melanoma Patient Network Europe with Bettina Ryll
Ep 48: CM 067 Final, 10-year analysis with Jedd Wolchok
Ep 47: TRICOTEL with Andreas Schmitt
Ep 46: Cemiplimab + Fianlimab (first report)
Ep 45: KEYNOTE 006 10 year follow-up
Ep 44: Treatment Beyond Progression
Ep 43: Mucosal Melanoma
Ep 42: RELATIVITY 020
Ep 41: Ipi 10 mg/kg v 3 mg/kg
Ep 40: CheckMate 238 Post-Recurrence Outcomes
Ep 39: LEAP 004 & 003
Ep 38: TIL v. Ipi
Ep 37: CheckMate 511
Ep 36: Indirect comparison CM 067 v RELA 047
Ep 35: End of Life care
Ep 34: CHOPIN & SCANDIUM trials for Uveal Melanoma
Ep 33: Percutaneous Hepatic Infusion for Uveal Melanoma
Ep 32: Ipi Nivo for Uveal Melanoma
Ep 31: Tebentafusp for Uveal Melanoma (Part Two)
Ep 30: Tebentafusp for Uveal Melanoma (Part One)
Ep 29: COMBI-AD long-term follow-up (10y)
Ep 28: RELATIVITY 048
Ep 27: NADINA in practice
Ep 26: NADINA w Christian Blank
Ep 25: Best of ASCO 2024 with Jeff Weber
Ep 24: SECOMBIT
Ep 23: DREAMSeq
Ep 22: Triplets for BRAF+ melanoma
Ep 21: Lifileucel
Ep 20: Neoadjuvant Nivolumab + Relatlimab
Ep 19: Single-dose of neoadjuvant pembro (UPenn study)
Ep 18: SD101 + Pembro
Ep 17: TVEC + Ipi
Ep 16: MASTERKEY 265
Ep 15: OPTiM
Ep 14: IMMUNED
Ep 13: SWOG S1801
Ep 12: PRADO
Ep 11: OpACIN-Neo
Ep 10: CheckMate 915
Ep 09: CheckMate 76K
Ep 08: KEYNOTE 716
Ep 07: KEYNOTE 054
Ep 06: CheckMate 238
Ep 05: SWOG S1404
Ep 04: EORTC 18071
Ep 03: CheckMate-204
Ep 02: RELATIVITY-047
Ep 01: CheckMate-067